NASDAQ:NSTG - NanoString Technologies Stock Price, Forecast & News

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies Inc (NASDAQ:NSTG) announced its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.64) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.10. The biotechnology company earned $30.60 million during the quarter, compared to the consensus estimate of $28.05 million. NanoString Technologies had a negative net margin of 72.30% and a negative return on equity of 118.32%. View NanoString Technologies' Earnings History.

NanoString Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for NanoString Technologies.

NanoString Technologies will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

NanoString Technologies updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $125.7-125.7 million, compared to the consensus revenue estimate of $121.36 million.

2 brokers have issued 1 year price targets for NanoString Technologies' stock. Their forecasts range from $28.00 to $35.00. On average, they expect NanoString Technologies' stock price to reach $31.50 in the next year. This suggests that the stock has a possible downside of 5.7%. View Analyst Price Targets for NanoString Technologies.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.

Headlines about NSTG stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. NanoString Technologies earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for NanoString Technologies.

Some companies that are related to NanoString Technologies include China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC) and Regenxbio (RGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Designer Brands (DBI), Bank Of The Ozarks (OZRK) and Eaton Vance Floating-Rate Income Trust (EFT).

NanoString Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (10.72%), Nikko Asset Management Americas Inc. (10.72%), ARK Investment Management LLC (8.55%), Cadian Capital Management LP (5.18%), Pictet Asset Management Ltd. (2.63%) and State Street Corp (1.90%). Company insiders that own NanoString Technologies stock include Charles P Waite, Jr, David W Ghesquiere, J Chad Brown, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Institutional Ownership Trends for NanoString Technologies.

NSTG stock was sold by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, Fred Alger Management LLC, ARK Investment Management LLC, Bank of America Corp DE, Acadian Asset Management LLC, Man Group plc, Sumitomo Mitsui Trust Holdings Inc. and AQR Capital Management LLC. Company insiders that have sold NanoString Technologies company stock in the last year include Charles P Waite, Jr, David W Ghesquiere, J Chad Brown, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, R Bradley Gray and William Young. View Insider Buying and Selling for NanoString Technologies.

NSTG stock was purchased by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Broadfin Capital LLC, Pictet Asset Management Ltd., Bank of New York Mellon Corp, UBS Group AG, Independent Advisor Alliance, Goldman Sachs Group Inc. and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for NanoString Technologies.

Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NSTG stock can currently be purchased for approximately $33.41.

NanoString Technologies has a market capitalization of $1.19 billion and generates $106.73 million in revenue each year. The biotechnology company earns $-77,400,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. NanoString Technologies employs 476 workers across the globe.View Additional Information About NanoString Technologies.

The official website for NanoString Technologies is http://www.nanostring.com/.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]